Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs CLR 1404 I-131 (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 27 Sep 2017 According to a Cellectar Biosciences media release, based on the data from fourth cohort, the company is planning to move into a fifth cohort using a multi-dose regimen.
    • 27 Sep 2017 Results from the fourth cohort published in the Cellectar Biosciences Media Release
    • 08 Aug 2017 Data published in a Cellectar Biosciences Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top